Virtu Financial: Market Maker May Not Get Its Growth

Explore Virtu Financial’s growth, capital shifts, and cycle risks. Learn why holding VIRT may be wise and the optimal entry ...

Financial Institutions Is Still Worth Banking On

Financial Institutions (FISI) remains undervalued despite improved fundamentals, with shares trading at attractive valuation ...

Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results

Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. “We are highly ...

The Market Is Giving Investors an Unbeatable Opportunity to Buy This Long-Term Artificial Intelligence (AI) Winner (Hint: Not Palantir or Nvidia)

Nvidia ( NVDA 0.53%) and Palantir Technologies ( PLTR +2.16%) are two of the biggest beneficiaries of investor optimism ...

New Data Reveals What Gen Alpha Wants Most And How We Should Respond

Discover interesting research on what Gen Alpha wants and learn how we should respond to ensure their success.